M.D., Senior Vice President, Chief Medical Officer & Medical Director, Biocept
Biography
Michael C. Dugan, M.D., leads Biocept’s clinical strategic development and oversees its CAP-accredited CLIA clinical laboratory. He is an experienced physician and biotechnology executive who has directed several major commercial reference laboratories and helped launch numerous novel molecular diagnostic assays and platforms used in oncology, infectious disease and public health applications such as cancer screening, monitoring, diagnosis and therapy selection. Dr. Dugan has held leadership positions with Clinical Genomics, Exact Sciences, Genzyme Genetics, Quest Diagnostics, AmeriPath, Specialty Laboratories and UCLA. Dr. Dugan is board-certified in Anatomic and Clinical Pathology. He received a bachelor’s degree in biology from the University of Notre Dame and a medical degree from the University of Arizona College of Medicine. He completed his post-graduate medical education in anatomic pathology at Yale-New Haven Hospital and continued training in pathology and laboratory medicine at Children’s Hospital Los Angeles and UCLA.
Talk
Cerebrospinal Fluid Assay Aids in Management of Metastatic Cancer with CNS Involvement
Approximately 50% of brain metastases have actionable mutations not detected in the primary tumor. A novel liquid biopsy assay detects and quantifies tumor cells in the cerebrospinal fluid and identifies actionable biomarkers. Recently presented data show the assay identifies actionable HER2 and genetic heterogeneity in patients with breast cancer that has metastasized to the brain.
Session Abstract – PMWC 2022 Silicon Valley
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.
Sessions:
- Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
Session Chair: Jimmy Lin, Freenome
- Peter Bach, Delfi Diagnostics
- Ash Alizadeh, Stanford
- Amir Ali Talasaz, Guardant Health
- Anne-Renee Hartman, Adela
- How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
Session Chair: Rebecca Brandes, Agilent
- Edward Abrahams, PMC
- Blandine Merino, Agilent
- Adrian Lee, UPMC - The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
- Minetta Liu, Natera - Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
Session Chair: Sam Salman, miR Scientific
- Frederick Baehner, Exact Sciences
- The Advantages of Exosomes as a Liquid Biopsy Based Markers
Session Chair: Johan Skog, Exosome Diagnostics
- Jamil Azzi, Harvard
- Dolores Di Vizio, Cedars-Sinai Medical Center
- Showcase
- Dave Mullarkey, Bluestar Genomics
- Stephane Mouradian, Personalis
- Michael Dugan, Biocept
- Priti Hegde, Foundation Medicine
- Steven Soper, The University of Kansas
- Maggie Rougier-Chapman, Personal Genome Diagnostics
- Daniel Kim, UCSC
